Legend Biotech Corp - ADR Stock

$34.63

3.43% yesterday

Nasdaq, Jun 27, 10:02 pm CET

ISIN

US52490G1022

Symbol

LEGN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Legend Biotech Corp - ADR Stock price

$34.63

-6.47 15.74% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+1.15 3.43%

ISIN

US52490G1022

Symbol

LEGN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$6.2b

Enterprise Value

$5.5b

Net debt

$-642.6m

Cash

$1.0b

Shares outstanding

368.1m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

8.46 | 5.94

EV/Sales

7.58 | 5.32

EV/FCF

negative

P/B

12.52

Financial Health

Equity Ratio

62.30%

Return on Equity

-17.01%

ROCE

-17.23%

ROIC

-60.71%

Debt/Equity

0.36

Financials (TTM | estimate)

Revenue

$728.3m | $1.0b

EBITDA

$-215.1m | $-134.0m

EBIT

$-237.9m

Net Income

$-218.2m | $-229.7m

Free Cash Flow

$-273.2m

Growth (TTM | estimate)

Revenue

112.46% | 65.49%

EBITDA

47.48% | 52.44%

EBIT

45.40%

Net Income

53.18% | -29.76%

Free Cash Flow

-2.82%

Margin (TTM | estimate)

Gross

65.51%

EBITDA

-29.53% | -12.91%

EBIT

-32.67%

Net

-29.95% | -22.13%

Free Cash Flow

-37.51%

EPS

$-0.59

FCF per Share

$-0.74

Short interest

14.97%

Employees

2.60k

Rev per Employee

$240.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Legend Biotech Corp - ADR Stock Analysis

Unlock Scores for Free

??

30 Analysts have issued a Legend Biotech Corp - ADR forecast:

27x Buy

90%

More details on Analyst Estimates Including Price Targets

30 Analysts have issued a Legend Biotech Corp - ADR forecast:

Buy

90%

Hold

10%

Analyst Estimates with Stock Price Targets

Financial data from Legend Biotech Corp - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	728 728	112% 112% 100%
- Direct Costs	251 251	54% 54% 34%
Gross Profit	477 477	166% 166% 66%
- Selling and Administrative Expenses	301 301	39% 39% 41%
- Research and Development Expense	415 415	4% 4% 57%
EBITDA	-215 -215	47% 47% -30%
- Depreciation and Amortization	23 23	13% 13% 3%
EBIT (Operating Income) EBIT	-238 -238	45% 45% -33%
Net Profit	-218 -218	53% 53% -30%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Legend Biotech Corp - ADR Stock News

Negative

Investors Business Daily

●

8 days ago

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

Neutral

GlobeNewsWire

●

25 days ago

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

SOMERSET, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new long-term results from the CARTITUDE-1 study in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. RRMM patients were treated with a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with no mai...

Neutral

GlobeNewsWire

●

about one month ago

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

SOMERSET, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new data evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients living with multiple myeloma will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2025 European Hematology ...

More Legend Biotech Corp - ADR News

Company Profile

Legend Biotech Corporation develops cell therapy solutions for cancer patients. The company was founded in 2014 and is based in Cayman Islands. The company operates as a subsidiary of Genscript Biotech Corporation.

Head office	Cayman Islands
CEO	Ying Huang
Employees	2,600
Founded	2014
Website	investors.legendbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now